{"filings":[{"id":1417160,"accession_number":"0001104659-26-080409","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-07-02T21:01:00+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance updates corporate presentation; guides FY26 revenue $350M-$370M, Q2 $86M-$88M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2026 revenue guidance of $86M-$88M; FY26 revenue guidance $350M-$370M; ~45% YoY quarterly growth.","Amtagvi commercial launch: >90 treatment centers, >1,500 patients treated; 5-year durability data: 31.4% ORR, 19.7% OS.","Lifileucel in NSCLC: 25.6% ORR, mDOR not reached at 25.4 months; Fast Track Designation; potential launch 2H27.","Soft tissue sarcoma Phase 2 registrational trial to commence 2Q 2026; 50% ORR in early data.","Cash $319M as of 3/31/26; manufacturing capacity up to 5K patients/year; broad payer coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":974836,"accession_number":"0001104659-26-072408","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-06-10T21:01:03+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Iovance's Amtagvi granted TGA approval in Australia for advanced melanoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Therapeutic Goods Administration of Australia approved Amtagvi for previously treated advanced melanoma.","Indicated for patients who received anti-PD-1 therapy and, if BRAF V600+, a BRAF/MEK inhibitor.","Third marketing authorization for Amtagvi; Iovance is authorizing its first Australian treatment center.","Australia has the world's highest melanoma rate, with ~17,000 new cases annually.","Approval based on Phase 2 C-144-01 trial results showing objective response rate and duration of response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92785,"accession_number":"0001104659-26-056782","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.","FY 2026 revenue guidance $350-$370M; Q2 2026 guidance $86-$88M.","Lifileucel in metastatic serous endometrial cancer: 40% confirmed ORR, 100% DCR in first 5 patients; FDA expedited path planned.","Cash ~$319M, expected to fund operations into 2028; R&D expenses down 12% vs Q4 2025.","UK MAA for lifileucel withdrawn for procedural reasons, will resubmit; EMA resubmission planned for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":71430000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103904,"accession_number":"0001104659-26-032774","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Wendy Yarno to retire from Iovance board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy Yarno will retire and not stand for re-election at the June 2026 annual meeting.","Yarno will serve out her current director term until the annual meeting.","Retirement is not due to any disagreement with the company on operations, policies, or practices.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103903,"accession_number":"0001104659-26-018837","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.","Gross margin improved to ~50% in Q4; cash $303M funds operations into Q3 2027.","FDA Fast Track granted for lifileucel in second-line advanced nonsquamous NSCLC; potential launch 2H27.","Real-world Amtagvi ORR ~44% at Tandem Meetings; 52% in patients with ≤2 prior lines.","Sarcoma early data: 50% ORR (6 evaluable); registrational trial to start Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":263502000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103902,"accession_number":"0001104659-26-002323","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.","Cash position of $307M as of 9/30/25, expected to fund operations into Q2 2027.","85 authorized treatment centers as of 12/31/25; over 1,000 patients treated with commercial and clinical TIL products.","Gross margin of 43% in Q3 2025; organization streamlined in Q3 2025 to support improved margins.","IOV-LUN-202 NSCLC trial enrollment complete; data update expected in 2026 with potential launch in H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120183,"accession_number":"0001104659-25-107426","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.","Cash and investments ~$307M; expected to fund operations into Q2 2027.","Full-year 2025 revenue guidance reaffirmed at $250-300M.","Lifileucel in NSCLC: ORR 26%, median DOR not reached at >25 months; IOV-LUN-202 enrollment to complete in 2026.","Amtagvi now at >80 U.S. authorized treatment centers; Health Canada approval in August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":176731000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136749,"accession_number":"0001104659-25-085650","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance posts updated corporate presentation for August 2025; no specific details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed an 8-K announcing a revised corporate presentation dated August 2025.","Presentation is used at healthcare conferences and for discussions with analysts and stockholders.","Exhibit 99.1 incorporated by reference but full content not provided in this filing excerpt.","No financial or clinical milestones were explicitly stated in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136748,"accession_number":"0001104659-25-081953","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Iovance Biotherapeutics enters $350M ATM equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Jefferies LLC to sell up to $350M of common stock in at-the-market offerings.","Jefferies will receive 3.0% commission on gross proceeds from any shares sold.","Sales may be made from time to time at the Company's discretion; no obligation to sell.","Prospectus supplement dated August 22, 2025, filed under existing S-3ASR registration statement.","Agreement is an amendment and restatement of prior open market sale agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136747,"accession_number":"0001104659-25-080304","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance's Amtagvi receives Health Canada approval for advanced melanoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Health Canada issued NOC/c for Amtagvi (lifileucel) for unresectable/metastatic melanoma after anti-PD-1 and targeted therapy.","First marketing authorization outside the U.S.; first T cell therapy approved for a solid tumor cancer in Canada.","Approval based on Phase 2 C-144-01 trial ORR and DOR by IRC; results published in 2022 and 2025 journals.","Iovance expects to authorize first Canadian treatment center within next few months; advancing ex-U.S. strategy.","Amtagvi is also being investigated in frontline advanced melanoma (Phase 3 TILVANCE-301) and other solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136746,"accession_number":"0001104659-25-075175","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.","Reiterated FY2025 total product revenue guidance of $250M-$300M.","Appointed Corleen Roche as CFO, effective after Q2 10-Q filing, replacing Matthew Rosinack.","Strategic restructuring reduces workforce by 19%, generating over $100M annual savings, extending cash runway into Q4 2026.","Over 100 patients treated with Amtagvi in Q2; network includes over 80 ATCs across 35 states."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":109276000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136745,"accession_number":"0001104659-25-067940","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Iovance appoints Corleen Roche as CFO effective August 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Corleen Roche, former CFO of CG Oncology and Immunome, replaces Matthew Rosinack as Principal Financial Officer.","Base salary of $600,000, one-time sign-on bonus of $50,000, and annual bonus target of 45% of base salary.","Receives 300,000 stock options and 150,000 RSUs, each vesting over 4 years with quarterly vesting after first anniversary.","Severance upon qualifying termination includes 12 months salary, pro-rated bonus, and accelerated equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136744,"accession_number":"0001104659-25-065781","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.","Matthew W. Rosinack appointed interim Principal Financial Officer and Principal Accounting Officer effective June 30, 2025.","Rosinack has been SVP, Finance since Sept 2021; prior roles at Berkeley Lights, ZELTIQ Aesthetics, FormFactor, and PwC.","No arrangements, family relationships, or transactions requiring disclosure in connection with Rosinack's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153983,"accession_number":"0001104659-25-059464","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.","No replacement named; company states departure is to pursue other opportunities.","Frederick G. Vogt serves as Interim CEO and President; CFO role remains unfilled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153982,"accession_number":"0001104659-25-058199","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iovance stockholders elect all director nominees, approve equity plan and audit ratification at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting held June 10, 2025; 254,281,338 shares (76.1% of outstanding) represented.","All seven director nominees elected; vote tallies ranged from 97.8M (Countouriotis) to 166.9M (Rothbaum).","Non-binding advisory vote on executive compensation approved: 158.8M for, 14.5M against, 0.8M abstain.","Ratification of Ernst & Young as independent auditor approved: 248.4M for, 4.9M against.","Amendments to 2018 Equity Plan (+12.5M shares) and 2020 ESPP (+1M shares) approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153981,"accession_number":"0001104659-25-046101","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance Q1 2025 revenue $49.3M; FY2025 guidance revised to $250-300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 product revenue $49.3M from Amtagvi ($43.6M) and Proleukin ($5.7M); net loss $116.2M ($0.36 diluted).","FY2025 total product revenue guidance revised to $250-300M reflecting launch dynamics and ATC growth trajectories.","Cash and investments $366M as of March 31, 2025; expected to fund operations into second half of 2026.","Q1 manufacturing capacity reduced by annual maintenance; fully resumed, targeting 100-110 commercial infusions in Q2.","On track for Amtagvi regulatory approvals in UK, EU, Canada in 2025; NSCLC registrational data in 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":49324000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172620,"accession_number":"0001104659-25-018212","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance Q4 2024 product revenue $73.7M; FY24 total $164.1M, achieving upper end of guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 product revenue of $164.1M, within $160-165M guidance; Amtagvi $103.6M, Proleukin $60.5M.","Net loss FY24 $372.2M ($1.28/share) vs $444.0M ($1.89/share) in FY23.","Reaffirms FY25 product revenue guidance of $450-475M; FY25 cash burn expected under $300M.","Cash position ~$422M as of Feb 26, 2025, expected to fund operations into H2 2026.","Dan Kirby named Chief Commercial Officer in Feb 2025; Raj Puri promoted to Chief Regulatory Officer Nov 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":164070000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172619,"accession_number":"0001104659-25-010729","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance appoints Dan Kirby as Chief Commercial Officer to lead Amtagvi launch expansion","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Kirby appointed CCO effective February 10, 2025.","Kirby brings cell therapy commercial experience from Orca Bio, Omeros, Celgene/BMS, and Juno.","He will lead U.S. launch growth of Amtagvi and expansion of Proleukin sales.","Iovance also preparing to enter new international markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189619,"accession_number":"0001104659-24-121612","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Iovance Biotherapeutics relocates HQ within same building, cutting monthly rent by ~64%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered 24-month sublease for 16,731 sq ft at 825 Industrial Road, San Carlos, starting Nov 15, 2024.","Monthly base rent: $99,550 first 12 months, $102,536 second 12 months, down from $279,541 under prior lease.","Terminated prior lease for 49,918 sq ft (Suite 400) effective by Dec 31, 2024, with a lease modification payment.","Relocation reflects cost reduction efforts with significantly reduced square footage and operating costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189618,"accession_number":"0001104659-24-115444","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance updates corporate presentation with Q3 2024 financials and pipeline status","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments of ~$404M as of Sept 30, 2024; Q3 product revenue of $58.6M.","FY 2024 product revenue guidance reaffirmed at $160–$165M.","56 Authorized Treatment Centers (ATCs) as of Nov 7, 2024; over 140 Amtagvi patients treated.","More than 250 million U.S. patient lives covered by payer policies.","Pipeline includes ongoing TILVANCE-301 Phase 3 trial in frontline advanced melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189617,"accession_number":"0001104659-24-115300","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance Q3 product revenue $58.6M; net loss narrows to $0.28/shr; FY24 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 product revenue $58.6M ($42.1M Amtagvi, $16.5M Proleukin); net loss $83.5M ($0.28/shr) vs $113.8M ($0.46/shr) YoY.","Reaffirms FY24 total product revenue guidance of $160-$165M and FY25 guidance of $450-$475M.","146 patients infused with Amtagvi since Apr 2024 launch; 82 infusions in Q3; 56 ATCs onboarded, targeting 70 by year-end.","Regulatory submissions accepted in EU, UK, Canada; potential approvals in 1H2025 (UK) and 2H2025 (EU, Canada).","Enrollment accelerating in IOV-LUN-202 Phase 2 NSCLC trial; potential accelerated U.S. approval for lifileucel in NSCLC expected in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":90376000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206118,"accession_number":"0001104659-24-087876","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance updates corporate presentation; FY24 product revenue guidance $160-165M, Q2 revenue $31.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2024 product revenue guidance of $160-165 million; Q2 2024 net product revenue $31.1 million.","Cash and investments ~$450 million as of July 24, 2024, after ~$200M ATM equity raise in Q2-Q3 2024.","51 Authorized Treatment Centers as of Aug 8, 2024; >225M patient lives covered; >55 patients treated.","Pipeline: TILVANCE-301 Phase 3 frontline melanoma enrolling; IOV-LUN-202 NSCLC registrational data expected 2025.","IOV-END-201 Phase 2 proof-of-concept trial in endometrial cancer initiated; IOV-4001 PD-1 inactivated TIL in Phase 1/2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206117,"accession_number":"0001104659-24-087259","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance posts Q2 product revenue $31.1M; guides FY24 $160-165M, FY25 $450-475M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $97.1M ($0.34/shr) vs. $106.5M ($0.47) a year ago; revenue $31.1M from Amtagvi ($12.8M) and Proleukin ($18.3M).","FY24 product revenue guidance $160-165M; FY25 $450-475M; Q3 2024 expected $53-55M.","Over 55 patients infused with Amtagvi since April; >50 ATCs in 29 states; >70 ATCs targeted by year-end.","Cash $449.6M as of July 24, up from $346.3M at Dec 2023, partly from ~$200M ATM equity raise.","Lifileucel pipeline: frontline melanoma TILVANCE-301 enrolling globally; NSCLC Phase 2 accelerating; endometrial cancer Phase 2 started."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":31821000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223163,"accession_number":"0001104659-24-075997","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance submits MAA to EMA for lifileucel in advanced melanoma; first of multiple global filings","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MAA seeks approval for lifileucel after prior PD-1 and BRAF/MEK therapy; would be first approved TIL therapy in EU.","Submission supported by Phase 2 C-144-01 trial data; validation expected Q3 2024; CHMP opinion in 2025.","Additional marketing submissions planned in Canada and UK in H2 2024, and Australia in 2025.","Targets >20,000 patients annually in U.S., EU, UK, Canada, and Australia with advanced melanoma.","EU expansion follows U.S. accelerated approval of lifileucel (Amtagvi) in February 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223162,"accession_number":"0001104659-24-070470","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iovance shareholders approve all proposals including equity plan increases at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; General McPeak did not stand for re-election, no disagreement.","Advisory vote on executive compensation passed with 173.75M for vs 10.03M against.","Ratification of Ernst & Young as auditor approved overwhelmingly (223.63M for).","Amendment to 2018 equity plan to increase authorized shares from 29.7M to 36.7M approved (177.46M for).","Amendment to 2020 ESPP to increase shares from 1.4M to 1.9M approved (182.04M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223161,"accession_number":"0001104659-24-067485","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance reports $363M cash, 50+ ATCs onboard for Amtagvi; frontline melanoma data shows 65.2% ORR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash position of ~$363M as of 3/31/2024; 600+ employees and 50+ payers covering 200M+ lives have approved Amtagvi for at least one patient.","50 Authorized Treatment Centers onboarded by 5/28/2024; targeting ~70 by end of 2024; 100+ patients enrolled by 5/9/2024.","EU submission for Amtagvi planned in 2Q2024; UK and Canada submissions in 2H2024.","Phase 2 frontline melanoma (IOV-COM-202 Cohort 1A) results: ORR 65.2%, CR 30.4%, median PFS not reached at 21.7 months follow-up.","Registrational TILVANCE-301 Phase 3 trial for frontline melanoma randomized first patient in 2Q2023; dual primary endpoints ORR and PFS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223160,"accession_number":"0001104659-24-064825","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance reports 65% ORR, 30% complete response rate for lifileucel + pembro in frontline melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR of 65.2% (30.4% CR, 34.8% PR) in 23 evaluable frontline advanced melanoma patients.","Median follow-up 21.7 months; nearly all responses ongoing; 53.3% of responders had duration ≥12 months.","All evaluable patients showed target lesion regression; safety consistent with known profiles of pembrolizumab, lymphodepletion, IL-2.","Data supports Phase 3 TILVANCE-301 trial with dual-primary endpoints ORR and PFS; interim ORR analysis may support accelerated approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223159,"accession_number":"0001104659-24-059322","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance reports Q1 net loss $113M; Amtagvi launch strong with 100+ patients enrolled across 40+ ATCs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $113.0M ($0.42 per share) vs $107.4M ($0.50) YoY; revenue $0.7M from Proleukin sales.","Cash, equivalents & investments $362.6M vs $346.3M at Dec 31, 2023; runway into H2 2025.","More than 100 patients enrolled for Amtagvi since Feb 16 FDA approval; ~50 ATCs on track by end of May, 70+ by year-end.","Manufacturing turnaround ~34 days; >75% of enrolled patients covered by private payers.","Regulatory filings for lifileucel on track in EU (Q2 2024), UK/Canada (H2 2024), Australia (2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":715000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223158,"accession_number":"0001104659-24-043158","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance settles derivative suit over director compensation; $600k fee, option cancellations","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Iovance cancels 12,796 (2019), 11,731 (2020), 8,603 (2021) options to non-employee directors; awards reduced below 75th peer percentile.","Governance reforms cap director comp at 75th percentile through 2027, limit options to 60% of equity grants, require annual comp consultant review.","Iovance pays $600,000 for plaintiff attorney fees (court approval required); no admission of wrongdoing by defendants.","Settlement hearing scheduled for July 11, 2024; if approved, derivative action dismissed with prejudice.","Stockholders may object by July 1, 2024 with proof of ownership and grounds; otherwise barred from contesting settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242648,"accession_number":"0001104659-24-041200","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Iovance Biotherapeutics director McPeak to retire; interim CEO Vogt nominated to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Merrill A. McPeak to retire and not stand for re-election at June 2024 annual meeting.","Frederick G. Vogt, Interim CEO and General Counsel, nominated to fill the vacancy.","Board unanimously adopted Fourth Amended and Restated Bylaws redefining 'Acting in Concert'.","McPeak's retirement is not due to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242647,"accession_number":"0001104659-24-030249","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Iovance's IOV-LUN-202 NSCLC trial; enrollment to resume","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Iovance to resume patient enrollment in registrational IOV-LUN-202 trial for LN-145 TIL therapy in NSCLC.","Additional safety and monitoring measures developed with FDA and independent data monitoring committee.","Iovance expects to complete enrollment of ~120 patients in registrational cohorts by 2025.","Updated Nov 2023 data showed 71% of confirmed responders had duration of response >6 months.","Initial preliminary data from July 2023 supported durable responses over available second-line chemotherapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242646,"accession_number":"0001104659-24-029057","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance reports $485M cash, AMTAGVI launch ongoing; partial clinical hold on lung TIL trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash position ~$485M as of 2/22/24, including $197.1M from Feb 2024 equity offering.","AMTAGVI (lifileucel) approved for advanced melanoma; 30 active ATCs at launch, targeting ~50 within 90 days.","FDA placed partial clinical hold on IOV-LUN-202 NSCLC trial on Dec 22, 2023; enrollment paused.","Phase 3 TILVANCE-301 frontline melanoma trial randomized first patient in 2Q23.","Proleukin acquired for £167.7M upfront; global rights secured for IL-2 supply in AMTAGVI regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242645,"accession_number":"0001104659-24-028704","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance reports $444M net loss for 2023; Amtagvi approved and launched Feb 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved Amtagvi (lifileucel) on Feb 16, 2024 — first T cell therapy for a solid tumor (advanced melanoma).","Net loss $444.0M ($1.89/share) for 2023 vs $395.9M ($2.49/share) in 2022; revenue $1.2M (first Proleukin sales).","Cash $346.3M at Dec 31, 2023; post Feb 2024 equity raise ~$485.2M, expected to fund operations into H2 2025.","~30 U.S. ATCs onboarded; ~50 expected by May 2024; at least 20 patients in process since approval.","MAA for EU expected H1 2024; UK and Canada submissions H2 2024; clinical hold on IOV-LUN-202 NSCLC trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1189000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242644,"accession_number":"0001104659-24-026578","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance closes $197.1M public offering of 23M shares at $9.15/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of 23,014,000 shares at $9.15 per share in underwritten offering.","Net proceeds expected to be approximately $197.1M after discounts and expenses.","Offering previously disclosed; closing occurred on February 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242643,"accession_number":"0001104659-24-025617","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Iovance prices $211M common stock offering at $9.15/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 23,014,000 shares at $9.15; gross proceeds ~$211M, net ~$197.1M.","Net proceeds to support AMTAGVI commercial launch, NSCLC study IOV-LUN-202, melanoma trial TILVANCE-301.","Underwriters include Jefferies, Barclays, Goldman Sachs; closing expected Feb 22, 2024.","Executive officers and directors subject to 60-day lock-up on stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242642,"accession_number":"0001104659-24-025082","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Iovance receives FDA accelerated approval for AMTAGVI (lifileucel) in advanced melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMTAGVI is first FDA-approved T cell therapy for a solid tumor cancer, indicated for advanced melanoma after anti-PD-1 and BRAF/MEK therapy.","Pivotal cohort (n=73) showed 31.5% objective response rate; median duration of response not reached at 18.6 months follow-up.","Preliminary cash, equivalents, investments, and restricted cash of $346.3M as of Dec 31, 2023, including $114.9M cash and equivalents.","Iovance Cell Therapy Center in Philadelphia has capacity for several thousand patients annually; 30+ authorized treatment centers prepared.","Phase 3 confirmatory trial TILVANCE-301 ongoing; boxed warning includes treatment-related mortality and severe cytopenia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242641,"accession_number":"0001104659-24-006804","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance discloses FDA clinical hold on NSCLC TIL trial; BLA for lifileucel in melanoma under review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on IOV-LUN-202 trial (NSCLC) on Dec 22, 2023; new enrollment paused.","BLA for lifileucel in advanced melanoma under FDA review with final label discussions ongoing.","Presentation reports $428M cash as of 9/30/23 and 90%+ manufacturing success rate.","Proleukin acquisition closed May 18, 2023 for £167.7M upfront; completed.","Melanoma data: ORR 31.4% (pooled cohorts 2&4) with median DOR not reached at 36.5 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242640,"accession_number":"0001104659-24-002290","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance updates pipeline: BLA under review, NSCLC trial on hold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BLA for lifileucel in advanced melanoma under FDA review; pre-license inspection of iCTC facility completed in 2023.","Clinical hold placed on IOV-LUN-202 NSCLC trial on Dec 22, 2023; enrollment paused, prior patients continue monitoring.","Phase 2 C-144-01 pooled melanoma data: ORR 31.4%, median DOR not reached, 41.7% of responses lasting ≥24 months.","Phase 3 TILVANCE-301 frontline melanoma trial first patient randomized in 2Q23; dual primary endpoints ORR and PFS.","Cash $428M as of Sep 30, 2023; Proleukin acquisition for £167.7M upfront closed May 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260038,"accession_number":"0001104659-23-129751","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places clinical hold on Iovance's LN-145 NSCLC trial after fatal adverse event","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on IOV-LUN-202 on Dec 22, 2023, after a Grade 5 fatal SAE potentially linked to preconditioning.","Enrollment paused; previously treated patients monitored; those with tumor resection continue with risk mitigations.","No impact on other Iovance trials or lifileucel BLA; PDUFA date remains Feb 24, 2024.","Updated Nov 2023 data: 71% of confirmed responders had duration of response >6 months.","Iovance will work with FDA to resume enrollment safely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260037,"accession_number":"0001104659-23-115226","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance reports Q3 net loss of $113.8M; BLA for lifileucel on track with PDUFA Feb 24, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $113.8M ($0.46/share) vs $99.6M ($0.63/share) in Q3 2022; revenue of $0.5M from Proleukin acquisition.","FDA Priority Review of lifileucel BLA on track; PDUFA date Feb 24, 2024; pre-approval inspections completed.","Onboarding completed at ~30 ATCs for potential U.S. commercial launch of lifileucel as first approved TIL therapy.","Cash position of $427.8M at Sept 30, 2023; raised ~$203.2M in Q3 from offerings; cash expected to fund operations into 2025.","Regulatory submissions for lifileucel in Europe and Canada planned for 2024; IOV-LUN-202 NSCLC trial enrollment on track for completion H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":707000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277321,"accession_number":"0001104659-23-100996","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA extends PDUFA date for Iovance's lifileucel BLA to Feb 24, 2024 due to resource constraints","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended PDUFA target action date for lifileucel BLA from prior to February 24, 2024, citing resource constraints.","No major review issues; all pre-approval inspections of clinical sites and manufacturing facilities completed successfully.","No advisory committee meeting planned; Priority Review and RMAT designation remain intact.","FDA agreed to work with Iovance to expedite remaining review, potentially allowing earlier approval.","Lifileucel seeks accelerated approval for advanced melanoma with no currently FDA approved therapies in that setting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277320,"accession_number":"0001104659-23-093553","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Iovance reports LN-145 + pembrolizumab 42.1% ORR in ICI-naïve mNSCLC trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 42.1% in ICI-naïve mNSCLC; 80% in treatment-naïve, 42.9% post-chemo, 14.3% EGFR-mutated post-TKI.","Tumor burden reduction in 76.5% of patients; durable responses deepening over time up to 15.4 months.","No new safety signals; TEAEs consistent with NMA-LD and IL-2 regimen.","Results support phase 3 study design for LN-145 in front-line mNSCLC.","Cash ~$478M (post-July offering) funds into end 2024; BLA filed for lifileucel in melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277319,"accession_number":"0001104659-23-088821","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance reports Q2 2023 net loss $106.5M, cash $317.3M; lifileucel PDUFA Nov 25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA set PDUFA date Nov 25, 2023 for lifileucel BLA in advanced melanoma under priority review.","Cash $317.3M at June 30; raised ~$161.4M from July public offering; expects funding into end of 2024.","Q2 2023 net loss $106.5M ($0.47/sh) vs $99.3M ($0.63/sh) in Q2 2022; R&D expense up to $86.3M.","Revenue $0.2M from Proleukin acquisition in May 2023; no revenue in prior-year period.","Registrational NSCLC trial IOV-LUN-202: 26.1% ORR in preliminary analysis; enrollment continuing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":238000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277318,"accession_number":"0001104659-23-080770","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance Biotherapeutics closes $172.5M public offering of 23M shares at $7.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 23,000,000 shares at $7.50 per share.","Gross proceeds $172.5M; net proceeds expected ~$161.4M after discounts and expenses.","Proceeds to fund lifileucel commercial launch prep, iCTC manufacturing, and clinical programs.","Full exercise of underwriters' option to purchase an additional 3 million shares.","Goldman Sachs & Co. LLC and Jefferies LLC acted as joint lead book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277317,"accession_number":"0001104659-23-080013","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Iovance prices $150M public offering of 20M shares at $7.50; underwriter option for 3M more","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 20M shares at $7.50/share for gross proceeds of $150M; net proceeds ~$140.2M.","Underwriters granted 30-day option for up to 3M additional shares; total offering up to 23M shares.","Proceeds to fund lifileucel commercial launch prep, manufacturing facility, and clinical programs.","Offering led by Goldman Sachs & Co. LLC and Jefferies LLC; expected to close July 13, 2023.","Executive officers and directors entered 90-day lock-up agreements on stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277316,"accession_number":"0001104659-23-079684","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Iovance reports ~$317M cash as of June 30; authorized shares increased to 500M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, short-term investments, and restricted cash ~$317M as of June 30, 2023 (unaudited).","Stockholders approved increase in authorized common stock from 300M to 500M at June 6 annual meeting; certificate filed June 9.","The cash estimate is subject to change upon completion of quarter-end closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277315,"accession_number":"0001104659-23-079364","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance gets FDA positive feedback for TIL therapy in NSCLC; 26.1% ORR in 23 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA Type B meeting supports IOV-LUN-202 trial design for accelerated approval of LN-145 in post-anti-PD-1 advanced NSCLC.","Preliminary data cut shows 26.1% ORR (6/23 patients) with one complete response and five partial responses; disease control rate 82.6%.","Plans to enroll ~120 patients in registrational trial; enrollment expected complete H2 2024.","Lifileucel BLA for advanced melanoma remains on Priority Review; PDUFA date Nov 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295215,"accession_number":"0001104659-23-072308","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Iovance enters $450M ATM equity offering with Jefferies, replaces prior program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered new Open Market Sale Agreement with Jefferies for up to $450M in at-the-market common stock sales.","Jefferies will receive commission of up to 3% of gross proceeds under the new program.","Prior ATM agreement dated November 18, 2022 was terminated concurrently.","Sales may be made through various methods including ordinary brokers' transactions on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295214,"accession_number":"0001104659-23-068579","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iovance Biotherapeutics shareholders approve all six proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; Wendy Dixon did not stand for re-election (no disagreement).","Advisory vote on executive compensation approved (152.1M for, 18.0M against).","Ratification of Ernst & Young as auditor approved (189.1M for).","Amendment to 2018 Equity Incentive Plan: shares increased from 20.7M to 29.7M.","ESPP shares increased from 500k to 1.4M; authorized common stock increased from 300M to 500M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295209,"accession_number":"0001104659-23-067589","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K/A","filed_at":"2023-06-02T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Iovance files audited financials for Proleukin acquisition; FY2022 revenue $21.6M, net loss $10.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proleukin revenue fell to $21.6M in FY2022 from $40.1M in FY2021; net loss of $10.2M vs profit $7.4M.","Impairment of intangible assets of $2.7M recorded in FY2022.","Auditors include going concern material uncertainty due to disposal to Iovance.","Unaudited pro forma financials for Q1 2023 and FY2022 filed as Exhibit 99.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1960190182.2216017,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-02T23:59:59+00:00|295209"}